Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beamion PANTUMOR-1: Zongertinib in HER2-altered solid tumours
2023-510429-14-00Phase 2Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, open-label, single-arm trial of zongertinib in HER2-mutant solid tumor (HER2m) and solid neoplasms, sponsored by Boehringer Ingelheim. Primary endpoint: Objective response rate. Planned start Sep 2024; status: authorised.
02
Drugs
zongertinib
03
Conditions
HER2-mutant solid tumor (HER2m)solid neoplasms
Beyond the preview
Go deeper on 2023-510429-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510429-14-00.